| Dr Mirna Farhat, MD | |
|
1537 Monroe St, Dearborn, MI 48124 | |
| (313) 789-7189 | |
| (313) 789-7188 |
| Full Name | Dr Mirna Farhat |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 19 Years |
| Location | 1537 Monroe St, Dearborn, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669703781 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 4301089788 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital - Dearborn | Dearborn, MI | Hospital |
| Harper University Hospital | Detroit, MI | Hospital |
| Detroit Receiving Hospital | Detroit, MI | Hospital |
| Sinai-grace Hospital | Detroit, MI | Hospital |
| Entity Name | Mirna Farhat Md Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033581434 PECOS PAC ID: 5799085825 Enrollment ID: O20151123000416 |
News Archive
Reuters: "Become tech-savvy. Bulk up. Venture abroad. Those appear to be among the most appealing alternatives for U.S. health insurers with their core U.S. markets in upheaval following passage of the healthcare overhaul, speakers at the Reuters Health Summit said this week.
The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.3 months)
Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.
TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mirna Farhat, MD 26672 Doxtator St, Dearborn Heights, MI 48127-3334 Ph: (313) 789-7189 | Dr Mirna Farhat, MD 1537 Monroe St, Dearborn, MI 48124 Ph: (313) 789-7189 |
News Archive
Reuters: "Become tech-savvy. Bulk up. Venture abroad. Those appear to be among the most appealing alternatives for U.S. health insurers with their core U.S. markets in upheaval following passage of the healthcare overhaul, speakers at the Reuters Health Summit said this week.
The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.3 months)
Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.
TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths.
› Verified 5 days ago
Albagir Mohamed Alarabi, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 | |
Dr. Rama V Thyagarajan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 18181 Oakwood Blvd Ste 101, Medical Office Building, Dearborn, MI 48124 Phone: 313-436-2426 Fax: 313-436-2440 | |
Adeeb M Atassi, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 18181 Oakwood Blvd, Suite Number 208, Dearborn, MI 48124 Phone: 313-563-3332 | |
Mihaela A. Lupu, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 18181 Oakwood Blvd, Ste 208, Dearborn, MI 48124 Phone: 313-271-5670 Fax: 313-271-1053 | |
Violet Asfour, Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 18100 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-436-2578 | |
Raed Haddad, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9720 Dix, Ste B, Dearborn, MI 48120 Phone: 313-843-1973 Fax: 313-843-1961 | |
Dr. Denise Kirsch, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 18101 Oakwood Blvd Ste 101, Dearborn, MI 48124 Phone: 313-436-2426 Fax: 313-436-2440 |